Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

NCT04738487 PHASE3 COMPLETED Results posted

Researchers are looking for new ways to treat people with metastatic non-small cell lung cancer (NSCLC) that is PD-L1 positive. * Metastatic means cancer that has spread to other parts of the body. * PD-L1 positive means that PD-L1 is found on the cancer cells. PD-L1 is a protein that can help the cancer hide from the body's immune system. The goal of this study is to learn if people who receive vibostolimab and pembrolizumab live longer overall and without the cancer getting worse than people who receive pembrolizumab alone.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	PHASE3
Status	COMPLETED
Enrolment	1264
Start date	Wed Apr 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jan 27 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Lung Neoplasms
• Non-Small-Cell Lung Carcinoma

Interventions

• Pembrolizumab/Vibostolimab
• Pembrolizumab

Countries

Hong Kong, Japan, Malaysia, Vietnam, South Korea, Philippines, Guatemala, Russia, Mexico, Thailand, United States, South Africa, Chile, Hungary, Romania, Canada, Brazil, Dominican Republic, Ukraine, Peru, China, Turkey (Türkiye), India